Orthocell Ltd
ASX:OCC
Orthocell Ltd
Research & Development
Orthocell Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orthocell Ltd
ASX:OCC
|
Research & Development
-AU$8.8m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-28%
|
|
|
Opthea Ltd
ASX:OPT
|
Research & Development
-$126.8m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-60%
|
CAGR 10-Years
-37%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Research & Development
-$34.8m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
CSL Ltd
ASX:CSL
|
Research & Development
-$1.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Research & Development
-AU$171.2m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Research & Development
-AU$65m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-76%
|
CAGR 10-Years
-36%
|
|
Orthocell Ltd
Glance View
Orthocell Ltd. engages in the development and commercialization of cell therapies and related technologies. The company is headquartered in Perth, Western Australia. The company went IPO on 2014-08-12. The firm is engaged in the development and commercialization of cell therapies and biological medical devices. The firm offers two main products, including CelGro and Ortho-ATI. CelGro is a naturally derived collagen medical device, which is designed for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons and cartilage. The company represents a paradigm shift in bone and soft tissue reconstruction. Ortho-ATI is a cell therapy for treatment of chronic tendon injuries. The treatment uses patient’s own tendon-derived cells to stimulate tendon regeneration and is delivered via a non-surgical ultrasound guided injection. The firm has a Good Manufacturing Process (GMP) facility. The facility is licensed by the Therapeutic Goods Administration (TGA) for the manufacture of human tendon cells and cartilage cells for the regeneration of damaged tendon and cartilage.
See Also
What is Orthocell Ltd's Research & Development?
Research & Development
-8.8m
AUD
Based on the financial report for Jun 30, 2025, Orthocell Ltd's Research & Development amounts to -8.8m AUD.
What is Orthocell Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-28%
Over the last year, the Research & Development growth was -2%. The average annual Research & Development growth rates for Orthocell Ltd have been -9% over the past three years , -10% over the past five years , and -28% over the past ten years .
